Echelon target $38 in a few years "The fact that the combination creates a solution that could generate high triple-digit million sales in a few years and billions within a few years after market launch is probably understood by very few. Evotec may even tailor iPSC cells for other indications from Sernova in the future. I think that some companies have been forced into action after yesterday's news. There will be no further partner in the diabetes area. Those who urgently need Sernova's Cell Pouch System can already start calculating a possible takeover valuation or can cancel projects. The heat is on. There will be a bidding war for Sernova - hopefully not too early. Sernova rating: STRONG BUY AGGRESSIVE up to 2.00 CAD/ price target by the end of September 2022: 5.00 CAD / 2nd price target 10.00 CAD by the end of March 2023. In the medium term (3-5 years) I see a price of 38 CAD. "